Navigation Links
AU5400 High-Volume Chemistry Immuno Analyzer

ProductsAU5400 High-Volume Chemistry Immuno Analyzer
Company Olympus America Diagnostics
Item AU5400 High-Volume Chemistry Immuno Analyzer
Features 
  • Configurable as the two module AU5421 or the three module AU5431 (upgradeable from the AU5421)
  • Choice of single or dual flowcell ISE module

    AU5421 (2 analyzer modules)

    • 3200 photometric tests/hour
    • 4100 tests/hour with single ISE
    • 5000 tests/hour with dual ISE

    AU5431 (3 analyzer modules)
    • 4800 photometric tests/hour
    • 5700 tests/hour with single ISE
    • 6600 tests/hour with dual ISE

  • Capacitance liquid level detection to ensure accurate sampling : 2-6 L for most tests
  • Continuous feed rack loader
  • Automated repeat testing (with optional unit) for abnormal sample results eliminates hands-on sample reprocessing
  • Multiple sized reagent cartridges hold from 100 to 6000+ tests to meet the needs of any size laboratory
  • CLIA Compliant
  • Easy to navigate software with drop-down menus, icons, and color-keyed graphics
Description The modular AU5400 is a high-volume analyzer that builds upon the field-proven reliability and productivity of the AU5200 analyzer and the latest Olympus technological advances. The Olympus AU5400 automates and consolidates chemistry-immuno testing with up to 147 on-board chemistries and throughput up to 6,600 tests per hour. Choose from Olympus 122 test menu, including chemistries and a broad menu of specialty tests. With a fully integrated track system to intelligently route samples to high-speed processing modules for simultaneous test processing, the AU5400 delivers high-productivity to meet real world lab needs.
Info Olympus America DiagnosticsCall Olympus America Diagnostics to buy products (US and Canada only; other locations use number below) USACanada1-866-651-9837

Customer Service: 1-800-645-8160, 610-391-2479
Web site: http://www.olympusamerica.com

Related medicine products :

1. CHECK-FLO Performer Introducers High-Volume Infusion Design
2. AU2700 High-Volume Chemistry Immuno Analyzer
3. NIAGARA® High-Volume Irrigation Pump
4. Aeroset Clinical Chemistry System
5. Advia 1650 Chemistry System
6. Advia 2400 Chemistry System
7. Express Plus Clinical Chemistry Analyzer
8. Dimension RxL Max™ Integrated Chemistry System 50/60HZ
9. Dimension RxL Max™ Integrated Chemistry System
10. Dimension Xpand Plus Integrated Chemistry System
11. Vitros 950 Chemistry System
The CHLAYMDIA OIA test delivers 100% specificity and 100% PPV with test results in 19 minutes. With as many as one-fourth of patients not returning for follow-up, this assay provides a test & treat
Shielding's Wrap-Around Apron is designed for front and back protection. This apron features extra wide shoulders distributing weight over a greater area to reduce fatigue.
Shielding's Velcro Adjustable Apron has two velcro flaps which aid in relieving weight off the shoulders. Its comfortable fit is attained by varying the position of flaps.
Upper arm protection
Medicine Products:
(Date:9/5/2008)...s the Latest Developments in Molecular,Testing and... /PRNewswire-USNewswire/ -- The practice of,pathol...g and the promise,of personalized medicine will ch...and other imaging technologies will change the way...ogists is taking a leadership role in,making sure ...
(Date:9/5/2008)...RNewswire-USNewswire/ -- The Health Resources,and ... million in grants to,increase and improve medical... grants continue President Bush,s historic expansi...w reach more economically,vulnerable and geographi...dministrator Elizabeth M. Duke said. "In 2007, mor...
(Date:9/5/2008)...tical ,anti-cloak, could bring objects out of hidi...-- Just in case someone develops a cloak of invisi... how to uncloak the objects it hides. , Accordi...in materials underneath an invisibility cloak woul...esearchers at Shanghai Jiao Tong University in Chi...
(Date:9/5/2008)...ain to commit to develop a National AIDS,Strategy ...p. 5 /PRNewswire-USNewswire/ -- The,Republican Nat...ion of the,domestic AIDS epidemic in the United St...erseas. Neither Presidential nominee Sen. John McC... mentioned AIDS in their remarks,to Convention del...
Breaking Medicine News(10 mins):Health News:Leaders in Pathology Meet in San Diego: Sept. 25 - 28, 2008 2Health News:HRSA Announces $39 Million in Grants to Expand, Improve Health Center Services 2Health News:Domestic AIDS Epidemic Ignored at Republican National Convention 2Health News:Domestic AIDS Epidemic Ignored at Republican National Convention 3
...UN Secretary General Ban Ki-moon urged governments...would save 14 million lives in coming years as// t...an's message aimed at stressing the importance of ...alth Organization (WHO) recently reported about th...
...This is one study finding bound to be paid attenti...t with the revelation that// long hours of watchin...nagers piling on the pounds. According to lead re...rcise and sport psychology at Loughborough Univers...
...Britain’s junior doctors have walked out of the re...d practical solution available’ by its mentors, to...aining Application Service. The government review...es in the Medical Training Application Service (MT...
...According to a senior medical advisor, a crackdown...y government. This is due to the pressure it puts ...ir Muir Grey, the program director of National Scr... magazine Pulse that there needs to be a regulatio...
Other Medicine News:Health News:Your Kids may Not Be Fat Because of too Much TV or Video Games 2Health News:Junior Doctors of UK Stage Walkout 2
(Date:9/5/2008).... 5 /PRNewswire-USNewswire/ -- The Florida,Technol...ed Florida,Atlantic University researcher Dr. Herb...r of the Center for Molecular Biology and,Biotechn..., and CHS,Resources LLC (CHS), $184,294 as part of...ssistance Grant program (SURECAG). SURECAG was,est...
(Date:9/5/2008)...t. 5 /PRNewswire-USNewswire/ -- A team of,research.... immigrants from,India and Pakistan take on the h...isks of prostate cancer among male immigrants and ...prostate cancer develop due to many reasons, but,e...le in these cancers,",said Jame Abraham, M.D., med...
(Date:9/4/2008)...t. 4 /- BioForm Medical,In...al clinical study of,Polidocanol, conducted in Ger...k KREUSSLER & Co. GmbH (Kreussler), successfully m...ed to FDA as part of a New Drug Application,(NDA) ...e EASI (Efficacy and safety of,Aethoxysklerol comp...
(Date:9/4/2008).... 4 /- Southern Research Institute,to...th (NIH) has selected,the organization to particip...Production Center Network (MLPCN). The MLPCN -- a ...olecular Libraries Program which is,designed to be...f the human,genome and validate future targets for...
Breaking Medicine Technology:Major State Grant Accelerates Research and Development of Novel Cancer Therapy 2Major State Grant Accelerates Research and Development of Novel Cancer Therapy 3Immigrants From India, Pakistan Face U.S. Prostate, Breast Cancer Risks 2338 Patient Pivotal Trial Demonstrates Safety and Effectiveness of Polidocanol Sclerotherapy Product for Varicose Vein Treatment 2338 Patient Pivotal Trial Demonstrates Safety and Effectiveness of Polidocanol Sclerotherapy Product for Varicose Vein Treatment 3338 Patient Pivotal Trial Demonstrates Safety and Effectiveness of Polidocanol Sclerotherapy Product for Varicose Vein Treatment 4338 Patient Pivotal Trial Demonstrates Safety and Effectiveness of Polidocanol Sclerotherapy Product for Varicose Vein Treatment 5Southern Research Institute Wins $14.7 Million NIH Award to Participate in Molecular Libraries Probe Production Center Network 2Southern Research Institute Wins $14.7 Million NIH Award to Participate in Molecular Libraries Probe Production Center Network 3Southern Research Institute Wins $14.7 Million NIH Award to Participate in Molecular Libraries Probe Production Center Network 4Prometic provides information for its Annual and Special Meeting of Shareholders 5041 1Prometic provides information for its Annual and Special Meeting of Shareholders 5041 2Sharing Miracles Television Program to Feature Leave it to Beaver Star Jerry Mathers 18181 1Sharing Miracles Television Program to Feature Leave it to Beaver Star Jerry Mathers 18181 2Sharing Miracles Television Program to Feature Leave it to Beaver Star Jerry Mathers 18181 3Sharing Miracles Television Program to Feature Leave it to Beaver Star Jerry Mathers 18181 4Sharing Miracles Television Program to Feature Leave it to Beaver Star Jerry Mathers 18181 5American Dental Association Stresses Good Oral Health During Pregnancy 18176 1American Dental Association Stresses Good Oral Health During Pregnancy 18176 2Message to Tucson Residents 3A Forgo Fad Dieting and Join the Campaign for Healthy Weight 18175 1Message to Tucson Residents 3A Forgo Fad Dieting and Join the Campaign for Healthy Weight 18175 2Message to Tucson Residents 3A Forgo Fad Dieting and Join the Campaign for Healthy Weight 18175 3Message to Tucson Residents 3A Forgo Fad Dieting and Join the Campaign for Healthy Weight 18175 4
...21, 2007 - Medical,professionals seeking to treat ...ed gram-negative pneumonia may have a new weapon:,...ndidate being,developed by Nektar Therapeutics (Na...evaluating the use of,NKTR-061 (Inhaled Amikacin) ...pital-acquired gram-negative pneumonia were,presen...
...K, Calif.--(BUSINESS WIRE)--May,21, 2007 - ChemGen...the publication of new clinical data relevant to t...ringtonine). The paper "Targeted,therapy and the T...by researchers Simona Soverini and colleagues at t...ume 92, pages 401-404) offers,insight into the gro...
Other Medicine Technology:Nektar Threraputics Announces Phase 2a Clinical Results Regarding,the use of NKTR-061 (Inhaled Amikacin) to Treat Gram-Negative,Hospital-Acquired Pneumonia Presented at the Annual American,Thoracic Society International Conference 2Nektar Threraputics Announces Phase 2a Clinical Results Regarding,the use of NKTR-061 (Inhaled Amikacin) to Treat Gram-Negative,Hospital-Acquired Pneumonia Presented at the Annual American,Thoracic Society International Conference 3Nektar Threraputics Announces Phase 2a Clinical Results Regarding,the use of NKTR-061 (Inhaled Amikacin) to Treat Gram-Negative,Hospital-Acquired Pneumonia Presented at the Annual American,Thoracic Society International Conference 4Nektar Threraputics Announces Phase 2a Clinical Results Regarding,the use of NKTR-061 (Inhaled Amikacin) to Treat Gram-Negative,Hospital-Acquired Pneumonia Presented at the Annual American,Thoracic Society International Conference 5Nektar Threraputics Announces Phase 2a Clinical Results Regarding,the use of NKTR-061 (Inhaled Amikacin) to Treat Gram-Negative,Hospital-Acquired Pneumonia Presented at the Annual American,Thoracic Society International Conference 6Nektar Threraputics Announces Phase 2a Clinical Results Regarding,the use of NKTR-061 (Inhaled Amikacin) to Treat Gram-Negative,Hospital-Acquired Pneumonia Presented at the Annual American,Thoracic Society International Conference 7Nektar Threraputics Announces Phase 2a Clinical Results Regarding,the use of NKTR-061 (Inhaled Amikacin) to Treat Gram-Negative,Hospital-Acquired Pneumonia Presented at the Annual American,Thoracic Society International Conference 8Nektar Threraputics Announces Phase 2a Clinical Results Regarding,the use of NKTR-061 (Inhaled Amikacin) to Treat Gram-Negative,Hospital-Acquired Pneumonia Presented at the Annual American,Thoracic Society International Conference 9Nektar Threraputics Announces Phase 2a Clinical Results Regarding,the use of NKTR-061 (Inhaled Amikacin) to Treat Gram-Negative,Hospital-Acquired Pneumonia Presented at the Annual American,Thoracic Society International Conference 10Nektar Threraputics Announces Phase 2a Clinical Results Regarding,the use of NKTR-061 (Inhaled Amikacin) to Treat Gram-Negative,Hospital-Acquired Pneumonia Presented at the Annual American,Thoracic Society International Conference 11Independent Publication Confirms Growing Therapeutic Challenge of,T315I Mutation in Patients with CML, Notes ChemGenex 2Independent Publication Confirms Growing Therapeutic Challenge of,T315I Mutation in Patients with CML, Notes ChemGenex 3